Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

NCT01849250 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

NIH

Sponsor class

Conditions

Benign Breast Neoplasm
Ductal Breast Carcinoma In Situ
Invasive Breast Carcinoma
Lobular Breast Carcinoma In Situ
Paget Disease of the Breast
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer

Interventions

DRUG: Docosahexaenoic Acid
OTHER: Placebo

Sponsor

National Cancer Institute (NCI)